IOL Chemicals & Pharmaceuticals announced that the 37th Annual General Meeting(AGM) of the company will be held on 23 August 2024.Powered by Capital Market - Live News

Net profit of IOL Chemicals & Pharmaceuticals declined 57.36% to Rs 27.62 crore in the quarter ended March 2024 as against Rs 64.78 crore during the previous quarter ended March 2023. Sales declined 14.18% to Rs 503.92 crore in the quarter ended March 2024 as against Rs 587.21 crore during the previous quarter ended March 2023.For the full year,net profit declined 3.39% to Rs 134.43 crore in the year ended March 2024 as against Rs 139.14 crore during the previous year ended March 2023. Sales declined 3.80% to Rs 2132.79 crore in the year ended March 2024 as against Rs 2217.11 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales503.92587.21 -14 2132.792217.11 -4 OPM %9.8316.23 -10.8110.18 - PBDT53.6399.15 -46 244.56234.81 4 PBT37.2087.04 -57 181.65188.65 -4 NP27.6264.78 -57 134.43139.14 -3 Powered by Capital Market - Live News

IOL Chemicals & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 May 2024Powered by Capital Market - Live News

IOL Chemicals & Pharmaceuticals announced that the company`s product �Metformin Hydrochloride� has been approved by Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA), China.This will enable the Company to export Metformin Hydrochloride in China Market. Metformin Hydrochloride is an antidiabetic drug which is used to manage the high blood sugar levels in diabetes patients. Powered by Capital Market - Live News

IOL Chemicals & Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 6 February 2024, inter alia, have recommended the interim dividend of Rs 5 per equity Share (i.e. 50%) , subject to the approval of the shareholders.Powered by Capital Market - Live News